These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 6540396)
1. Low-dose CU 32-085 (mesulergine) in previously untreated Parkinson's disease. Bonnet AM; Esteguy M; Guimaraes J; Lhermitte F; Agid Y Neurology; 1984 Aug; 34(8):1127-8. PubMed ID: 6540396 [No Abstract] [Full Text] [Related]
2. Mesulergine (CU32-085) in the treatment of Parkinson's disease. Pfeiffer RF; Wilken K; Glaeske C Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700 [TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled study of mesulergine in Parkinson's disease. Jankovic J; Orman J; Jansson B Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692 [TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease: a comparison of mesulergine and bromocriptine. Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of pergolide and mesulergine. Lieberman AN; Gopinathan G; Neophytides A Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Jori MC; Franceschi M; Giusti MC; Canal N; Piolti R; Frattola L; Bassi S; Calloni E; Mamoli A; Camerlingo M Adv Neurol; 1990; 53():539-43. PubMed ID: 2239494 [No Abstract] [Full Text] [Related]
13. Lisuride and pergolide in Parkinson's disease. Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769 [No Abstract] [Full Text] [Related]
14. Cabergoline in Parkinson's disease. Horstink MW; Berger HJ; van de Vlasakker CJ Neurology; 1995 Jun; 45(6):1233-4. PubMed ID: 7632296 [No Abstract] [Full Text] [Related]
15. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease. Diamond SG; Markham CH Adv Neurol; 1984; 40():537-9. PubMed ID: 6695633 [No Abstract] [Full Text] [Related]
16. Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease. Navan P; Bain PG J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):602-3. PubMed ID: 12397168 [No Abstract] [Full Text] [Related]
17. CQP 201-403 in Parkinson's disease: an open-label pilot study. Pfeiffer RF; Herrera LH; Glaeske CS; Hofman RE Mov Disord; 1989; 4(3):278-81. PubMed ID: 2571083 [TBL] [Abstract][Full Text] [Related]
18. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease. Klawans HL; Tanner CM; Glatt S; Goetz CG Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592 [No Abstract] [Full Text] [Related]
19. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Frans E; Dom R; Demedts M Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483 [TBL] [Abstract][Full Text] [Related]
20. [Clinical study of pergolide in Parkinson's disease]. Gonce M; Delwaide PJ Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]